For instance, Enhancer of Zeste Homolog 2 inhibitors (EZH2 inhibitors) can alleviate intrinsic tumor resistance by epigenetically derepressing pro-inflammatory SASP genes, thereby increasing the production of C-X-C Motif Chemokine Ligands 9 and 10 (CXCL9 and CXCL10), which promote effector CD8+ T-cell infiltration [127]. This evidence concerns the gene EZH2 and neoplasm.